 WALTHAM, Mass., July 26, 2021 GLOBE NEWSWIRE -- Apellis Pharmaceuticals, Inc. Nasdaq:APLS, a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions the Exchange Transactions with certain holders of its 3.500 Convertible Senior Notes due 2026 the Notes. In the Exchange Transactions, the holders exchanged approximately 201.1 million in aggregate principal amount of Notes and Apellis issued an aggregate of 5,992,217 shares of its common stock. 